Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

Published: May 12, 2021
 
 
MALVERN, Pa.--(BUSINESS WIRE)-- Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today announced their launch with a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling research.
“We are excited to announce our collaboration with Shifa to address the unmet need for oral drugs that can treat dyslipidemia without the need for injections,” said Chris Garabedian, Founder, Chairman and Chief Executive Officer of Xontogeny. “The expertise of our team at Xontogeny complements that of the team at Shifa, and we are aligned on the key milestones we plan to achieve with this seed investment.”

Related Keywords

Boston ,Massachusetts ,United States ,Sherin Abdel Meguid ,Gianna Hoffman Luca ,Chris Garabedian ,Shaker Mousa ,Nabil Elshourbagy ,Albany College Of Pharmacy ,Shifa Biomedical Corporation ,Health Sciences ,Biomedical Corporation ,Chief Executive Officer ,Harold Meyers ,Senior Associate ,Albany College ,Resume ,Careers ,Hifa Launches With Seed Financing To Address Cardiovascular Disease By Developing Orally Bioavailable Drugs For The Treatment Of Dyslipidemia ,Iospace ,Advice ,போஸ்டன் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,கிறிஸ் கரபெடியன் ,அல்பானி கல்லூரி ஆஃப் மருந்தகம் ,ஆரோக்கியம் அறிவியல் ,உயிர் மருத்துவ நிறுவனம் ,தலைமை நிர்வாகி அதிகாரி ,ஹரோல்ட் மேயர்கள் ,மூத்தவர் இணை ,அல்பானி கல்லூரி ,தற்குறிப்பு ,